1 / 6

Simeprevir vs Telaprevir in GT1 ATTAIN Trial

A study comparing the effectiveness of Simeprevir and Telaprevir with Peginterferon and Ribavirin in treating Hepatitis C genotype 1 patients who have previously undergone treatment.

kvaughn
Download Presentation

Simeprevir vs Telaprevir in GT1 ATTAIN Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 TreatmentExperienced Simeprevir versus Telaprevirwith PR in GT1 ATTAIN Trial Reddy KR, et al. Lancet Infect Dis. 2015;15:27-35.

  2. SimeprevirvsTelaprevir with Peginterferon + Ribavirin in GT1ATTAIN: Study Features Source: Reddy KR, et al. Lancet Infect Dis. 2015;15:27-35.

  3. SimeprevirvsTelaprevir with Peginterferon + Ribavirin in GT1ATTAIN: Study Design Week 0 12 48 Simeprevir N = 379 SVR12 Peginterferon+ Ribavirin HCV GT-1Treatment Experienced Telaprevir N = 384 SVR12 Peginterferon+ Ribavirin Drug DosingSimeprevir: 150 mg once dailyTelaprevir: 750 mg three times daily Peginterferon alfa-2a (PEG): 180 mcg/week Ribavirin (RBV) weight-based (in 2 divided doses): 1000 mg if < 75kg or 1200 mg/day if ≥ 75kg Source: Reddy KR, et al. Lancet Infect Dis. 2015;15:27-35.

  4. SimeprevirvsTelaprevir with Peginterferon + Ribavirin in GT1ATTAIN: Results ATTAIN: SVR12 by Prior Treatment Response 202/379 210/384 102/234 110/238 101/145 100/146 PR = peginterferon plus ribavirin Source: Reddy KR, et al. Lancet Infect Dis. 2015;15:27-35.

  5. SimeprevirvsTelaprevir with Peginterferon+ Ribavirin in GT1ATTAIN: Conclusions Source: Reddy KR, et al. Lancet Infect Dis. 2015;15:27-35.

  6. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related